MYRTHES ANNA MARAGNA TOLEDO BARROS
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/60 - Laboratório de Imunologia Clínica e Alergia, Hospital das Clínicas, Faculdade de Medicina
LIM/60 - Laboratório de Imunologia Clínica e Alergia, Hospital das Clínicas, Faculdade de Medicina
14 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 14
- Common variable immunodeficiency: an important but little-known risk factor for gastric cancer(2021) KREIN, PAULA; YOGOLARE, GUSTAVO GONÇALVES; PEREIRA, MARINA ALESSANDRA; GRECCO, OCTAVIO; BARROS, MYRTHES ANNA MARAGNA TOLEDO; DIAS, ANDRE RONCON; MARINHO, ANA KAROLINA BARRETO BERSELLI; ZILBERSTEIN, BRUNO; KOKRON, CRISTINA MARIA; RIBEIRO-JÚNIOR, ULYSSES; KALIL, JORGE; NAHAS, SERGIO CARLOS; RAMOS, MARCUS FERNANDO KODAMA PERTILLEABSTRACT Introduction: although it is a rare disease, common variable immunodeficiency (CVID) stands out as the most frequent primary symptomatic immunodeficiency. Carriers are prone to a variety of recurrent bacterial infections, in addition to the risk of developing autoimmune diseases and neoplasms including gastric cancer (GC). Despite the recognized risk, there are no specific standardized protocols for the management of GC in these patients, so the reported oncological results are varied. Thus, this study aims to describe the clinicopathological characteristics and prognosis of patients with CVID undergoing surgical treatment of GC. Methods: all patients with GC undergoing surgical treatment between 2009 and 2020 were retrospectively evaluated. Later, patients diagnosed with CVID were identified and this group was compared with the remaining patients without any immunodeficiency. Results: among the 1101 patients with GC evaluated in the period, 10 had some type of immunodeficiency, and 5 were diagnosed with CVID. Patients with CVID had younger age, lower BMI, and smaller lesions compared to those without CVID. Four patients underwent curative gastrectomy and one patient underwent jejunostomy. Two patients died (1 palliative and 1 curative) and one patient had disease recurrence. There was no statistically significant difference regarding the incidence of postoperative complications and survival between the evaluated groups. Conclusion: the CVID incidence in patients with GC undergoing surgical treatment was 0.5%, occurring at a less advanced age, but with no difference regarding surgical and oncological results.
conferenceObject Systemic inflammatory syndromes with immunodysregulatory phenotype: clinical characteristics, genetic findings and therapeutic response(2021) PEREIRA, Grazielly Pereira; PRADO, Alex; BRANDAO, Jaqueline Brandao; ZANETTI, Francine Zanetti; ALBERTO, Nazoneth; ALBERTO, Samucanda; KALIL, Jorge; FONSECA, Luiz; CASTRO, Fabio Castro; TOLEDO-BARROS, Myrthes; MENDONCA, Leonardo MendoncaconferenceObject Frequency of Follicular T cells in a cohort of Brazilian Common Variable Immunodeficiency (CVID) patients(2021) KOKRON, Cristina; ZILINSKI, Fernando; SANTOS, Bianca; COUTINHO, Erica; APOSTOLICO, Juliana; ANDRADE, Milena; MARINHO, Ana Karolina; BARROS, Myrthes; GRECCO, Octavio; KALIL, JorgeconferenceObject Cancer mortality in a cohort of 202 common variable immunodeficiency patients from Sao Paulo, Brazil, followed for up to forty years(2021) FONSECA, Luiz; BARROS, Myrthes; KOKRON, Cristina; GRECCO, Octavio; BARRETO, Ana; KALIL, Jorge- Outcome of SARS-CoV-2 Infection in 121 Patients with Inborn Errors of Immunity: A Cross-Sectional Study(2021) GOUDOURIS, Ekaterini Simoes; PINTO-MARIZ, Fernanda; MENDONCA, Leonardo Oliveira; ARANDA, Carolina Sanchez; GUIMARAES, Rafaela Rolla; KOKRON, Cristina; BARROS, Myrthes Toledo; ANISIO, Flavia; ALONSO, Maria Luiza Oliva; MARCELINO, Fernanda; VALLE, Solange Oliveira Rodrigues; DORTAS JUNIOR, Sergio; BARRETO, Irma Douglas Paes; FERREIRA, Janaira Fernandes Severo; ROXO-JUNIOR, Persio; SILVA, Almerinda Maria do Rego; CAMPINHOS, Fernanda Lugao; BONFIM, Carmem; LOTH, Gisele; FERNANDES, Juliana Folloni; GARCIA, Julia Lopes; CAPELO, Albertina; TAKANO, Olga Akiko; NADAF, Maria Isabel Valdomir; TOLEDO, Eliana C.; CUNHA, Luciana Araujo Oliveira; GESU, Regina Sumiko Watanabe Di; SCHIDLOWSKI, Laire; FILLIPO, Priscila; BICHUETTI-SILVA, Danielli C.; SOLDATELI, Gustavo; FERRARONI, Natasha Reboucas; DANTAS, Ellen de Oliveira; PESTANA, Simone; MANSOUR, Eli; ULAF, Raisa Gusso; PRANDO, Carolina; CONDINO-NETO, Antonio; GRUMACH, Anete SevciovicPurpose There is still scarce data on SARS-CoV-2 infection in patients with Inborn Errors of Immunity (IEI) and many unresolved questions. We aimed to describe the clinical outcome of SARS-CoV-2 infection in Brazilian IEI patients and identify factors influencing the infection. Methods We did a cross-sectional, multicenter study that included patients of any age affected by IEI and SARS-CoV-2 infection. The variables studied were sex, age, type of IEI, comorbidities (number and type), treatment in use for IEI, clinical manifestations and severity of SARS-CoV-2 infection. Results 121 patients were included: 55.4% female, ages from six months to 74 yo (median age = 25.1 yo). Most patients had predominantly antibody deficiency (n = 53). The infection was mostly asymptomatic (n = 21) and mild (n = 66), and one child had multisystem inflammatory syndrome (MIS-C). We could not observe sex-related susceptibility, and there was a weak correlation between age and severity of infection. The number of comorbidities was higher in severe cases, particularly bronchiectasis and cardiopathy. There were no severe cases in hereditary angioedema patients. Six patients aged 2 to 74 years died, three of them with antibody deficiency. Conclusion The outcome was mild in most patients, but the Case Fatality Ratio was higher than in the general population. However, the type of IEI was not a determining factor for severity, except for complement deficiencies linked to milder COVID-19. The severity of SARS-CoV-2 infection seems to be more related to older age, a higher number of comorbidities and type of comorbidities (bronchiectasis and cardiopathy).
bookPart Doenças autoinflamatórias(2021) MENDONçA, Leonardo Oliveira; BARROS, Myrthes Toledo; KALIL FILHO, Jorge Elias; GATTORNO, MarcobookPart Papel biológico da IgE(2021) BARROS, Myrthes Toledo; COUTINHO, Érica Maria Martins; MENDONçA, Leonardo OliveirabookPart Autoimunidade: diferencial com doenças alérgicas(2021) BARROS, Myrthes Toledo; GONçALVES, Danilo GoisconferenceObject Difference in clinical characteristics of patients with common variable immunodeficiency (CVID) according to pulmonary alterations - A cohort of 182 patients from a Brazilian tertiary hospital(2021) FRANCO, Priscila; AGONDI, Rosana; PEREIRA, Grazielly; PEREIRA, G. F.; GRECCO, Octavio; MARINHO, Ana Karolina; BARROS, Myrthes Toledo; BARROS, Myrthes T.; KALIL, Jorge; KOKRON, Cristina- Immunological repertoire linked to PSTPIP1-associated myeloid-related inflammatory (PAMI) syndrome(2021) MENDONCA, Leonardo Oliveira; TERRERI, Maria Teresa; OSAKU, Fabiane Mitie; BARROS, Samar Freschi; KOHLER, Karen Francine; PRADO, Alex Isidoro; BARROS, Myrthes Toledo; KALIL, Jorge; CASTRO, Fabio Fernandes MoratoBackground Mutations along PSTPIP1 gene are associated to two specific conditions, PAPA syndrome and PAMI syndrome, both autoinflammatory disorders associated to disturbances in cytoskeleton formation. Immunological aspects of PAMI syndrome has not yet been reported neither the clinical impact on therapeutical decisions. Methods Clinical data of patients records were retrospectively accessed. Genomic DNA were extracted and sequenced following standard procedures. Peripheral lymphocytes were quantified in T, B e FOXP3 phenotypes. Results We describe two related patients with PAMI syndrome harboring the usual E250K mutation. Anti-IL1 therapy could partially control the disease in the index patient. A broad spectrum of immunological effects as well as an aberrant expression of FOXP3 could be observed. Conclusions Here we report two related brazilian patients with PAMI syndromes harboring the E250K mutation in PSTPIP1, their immunological aspects and the therapeutical response to canakinumab.